Interleukin‐receptor antagonist and tumor necrosis factor inhibitors for theprimary and secondary prevention of atherosclerotic cardiovascular diseases.

Abstract

Objectives:

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

To assess the clinical benefits and harms of interleukin‐receptor antagonists and tumor necrosis factor (TNF) inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases.

To determine whether interleukin‐receptor antagonists or TNF inhibitors, provided to people both with and without pre‐existing cardiovascular disease, are: useful in preventing adverse cardiovascular outcomes; and safe.